Evidence map›Paper›PMID 40405477›Full record

ArticleCell cycle (Georgetown, Tex.)

Cell-cycle dependent inhibition of BRCA1 signaling by the lysine methyltransferase SET8.

Yannick Perez, Fatima Alhourani, Julie Patouillard, Cyril Ribeyre, Marion Larroque, Véronique Baldin, David Lleres, Charlotte Grimaud, Eric Julien

Abstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yannick PerezInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer (ICM), Montpellier, France.
Fatima AlhouraniInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer (ICM), Montpellier, France.
Julie PatouillardInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer (ICM), Montpellier, France.
Cyril RibeyreUniversity of Montpellier, Montpellier, France.
Marion LarroqueInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer (ICM), Montpellier, France.
Véronique BaldinInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer (ICM), Montpellier, France.
David LleresUniversity of Montpellier, Montpellier, France.
Charlotte GrimaudInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer (ICM), Montpellier, France.
Eric JulienInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer (ICM), Montpellier, France.ORCID 0000-0003-2976-666X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cell-cycle regulated methyltransferase SET8 is the sole enzyme responsible for the mono-methylation of histone H4 at lysine 20 (H4K20) that is the substrate for di- and trimethylation mainly by SUV4-20Hs enzymes. Both SET8 and SUV4-20Hs have been implicated in regulating DNA repair pathway choice through the inverse affinities of BRCA1-BARD1 and 53BP1 complexes for disparate methylation states of H4K20. However, the precise and respective functions of each H4K20 methyltransferase in DNA repair pathways remain to be clarified. Here, we show that SET8 acts as a potent chromatin inhibitor of homologous recombination and that its timely degradation during DNA replication is essential for the spontaneous nuclear focal accumulation of BRCA1 and RAD51 complexes during the S phase. Strikingly, the anti-recombinogenic function of SET8 is independent of SUV4-20H activity but requires the subsequent recruitment of the ubiquitin ligase RNF168. Moreover, we show that SET8-induced BRCA1 inhibition is not necessarily related to the loss of BARD1 binding to unmethylated histone H4K20. Instead, it is largely caused by the accumulation of 53BP1 in a manner depending on the concerted activities of SET8 and RNF168 on chromatin. Conversely, the lack of SET8 and H4K20 mono-methylation on newly assembly chromatin after DNA replication led to the untimely accumulation of BRCA1 on chromatin at the subsequent G1 phase. Altogether, these results establish the

Indexed as

BRCA1 ProteinCell CycleHistone-Lysine N-MethyltransferaseSignal TransductionChromatinDNA ReplicationHistonesHomologous RecombinationHumansRad51 RecombinaseTumor Suppressor p53-Binding Protein 1Tumor Suppressor ProteinsUbiquitin-Protein LigasesBARD1 protein, humanBRCA1 ProteinBRCA1 protein, humanChromatinHistone-Lysine N-MethyltransferaseHistonesKMT5A protein, humanRad51 RecombinaseTP53BP1 protein, humanTumor Suppressor p53-Binding Protein 1Tumor Suppressor ProteinsUbiquitin-Protein Ligases53BP1BRCA1DNA repair & chromatinH4K20 methylationSET8

Identifiers

PMID40405477
PMCPMC12380219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.